These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1387 related items for PubMed ID: 24449821

  • 1. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
    Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.
    Circulation; 2014 Mar 25; 129(12):1320-31. PubMed ID: 24449821
    [Abstract] [Full Text] [Related]

  • 2. Degradation of platelet-von Willebrand factor complexes by plasmin: an alternative/backup mechanism to ADAMTS13.
    Chauhan AK.
    Circulation; 2014 Mar 25; 129(12):1273-5. PubMed ID: 24449820
    [No Abstract] [Full Text] [Related]

  • 3. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
    El Otmani H, Frunt R, Smits S, Barendrecht AD, de Maat S, Fijnheer R, Lenting PJ, Tersteeg C.
    Blood; 2024 May 16; 143(20):2089-2098. PubMed ID: 38271661
    [Abstract] [Full Text] [Related]

  • 4. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
    de Maat S, Clark CC, Barendrecht AD, Smits S, van Kleef ND, El Otmani H, Waning M, van Moorsel M, Szardenings M, Delaroque N, Vercruysse K, Urbanus RT, Sebastian S, Lenting PJ, Hagemeyer CE, Renné T, Vanhoorelbeke K, Tersteeg C, Maas C.
    Blood; 2022 Jan 27; 139(4):597-607. PubMed ID: 34752601
    [Abstract] [Full Text] [Related]

  • 5. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
    Shin Y, Miyake H, Togashi K, Hiratsuka R, Endou-Ohnishi K, Imamura Y.
    J Biochem; 2018 May 01; 163(5):381-389. PubMed ID: 29228282
    [Abstract] [Full Text] [Related]

  • 6. Response to letter regarding article, "plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".
    Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.
    Circulation; 2015 Jan 13; 131(2):e19-20. PubMed ID: 25583061
    [No Abstract] [Full Text] [Related]

  • 7. Letter by Hugenholtz and Lisman regarding article, "plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".
    Hugenholtz GC, Lisman T.
    Circulation; 2015 Jan 13; 131(2):e18. PubMed ID: 25583060
    [No Abstract] [Full Text] [Related]

  • 8. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
    Tersteeg C, Joly BS, Gils A, Lijnen R, Deckmyn H, Declerck PJ, Plaimauer B, Coppo P, Veyradier A, Maas C, De Meyer SF, Vanhoorelbeke K.
    J Thromb Haemost; 2017 Dec 13; 15(12):2432-2442. PubMed ID: 28981198
    [Abstract] [Full Text] [Related]

  • 9. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE, Moake JL, Miyata T, George JN.
    Hematology Am Soc Hematol Educ Program; 2004 Dec 13; ():407-23. PubMed ID: 15561695
    [Abstract] [Full Text] [Related]

  • 10. [ADAMTS13-Mediated Proteolytic Cleavage of Unusually Large von Willebrand Factor Polymers on Endothelial Cells in the Absence of Fluid Shear Stress].
    Zhao SC, Li H, Wang M, Zhao YH, Li XJ, Jin SY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr 13; 32(2):532-540. PubMed ID: 38660863
    [Abstract] [Full Text] [Related]

  • 11. [ADAMTS13, von Willebrand factor specific cleaving protease].
    Veyradier A, Coppo P.
    Med Sci (Paris); 2011 Dec 13; 27(12):1097-105. PubMed ID: 22192749
    [Abstract] [Full Text] [Related]

  • 12. Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
    Brophy TM, Ward SE, McGimsey TR, Schneppenheim S, Drakeford C, O'Sullivan JM, Chion A, Budde U, O'Donnell JS.
    Arterioscler Thromb Vasc Biol; 2017 May 13; 37(5):845-855. PubMed ID: 28279966
    [Abstract] [Full Text] [Related]

  • 13. The potential therapeutic benefit of targeting ADAMTS13 activity.
    Eerenberg ES, Levi M.
    Semin Thromb Hemost; 2014 Feb 13; 40(1):28-33. PubMed ID: 24338607
    [Abstract] [Full Text] [Related]

  • 14. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
    Lian EC.
    Semin Thromb Hemost; 2005 Dec 13; 31(6):625-32. PubMed ID: 16388413
    [Abstract] [Full Text] [Related]

  • 15. A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
    Hoirisch-Clapauch S, Nardi AE.
    Med Hypotheses; 2014 Dec 13; 83(6):747-50. PubMed ID: 25459148
    [Abstract] [Full Text] [Related]

  • 16. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
    Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, Lijnen HR, Vanhoorelbeke K.
    J Thromb Haemost; 2010 Sep 13; 8(9):2053-62. PubMed ID: 20553378
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.
    Tersteeg C, Fijnheer R, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de Maat S, Maas C.
    Semin Thromb Hemost; 2016 Feb 13; 42(1):9-17. PubMed ID: 26595154
    [Abstract] [Full Text] [Related]

  • 19. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K.
    Arterioscler Thromb Vasc Biol; 2015 Nov 13; 35(11):2336-42. PubMed ID: 26338302
    [Abstract] [Full Text] [Related]

  • 20. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U, Schneppenheim R.
    Hamostaseologie; 2014 Nov 13; 34(3):215-25. PubMed ID: 25010251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.